Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 27, 2017

High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a) (S44.005)

Raymond Hupperts, Joost Smolders, Reinhard Vieth, Trygve Holmøy, Kurt Marhardt, Myriam Schluep, Joep Killestein, Frederik Barkhof, Luigi Maria Grimaldi, Manolo Beelke
First published April 17, 2017,
Raymond Hupperts
1Orbis Medisch Centrum, Maastricht University Medical Center Sittard Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost Smolders
2Canisus Wilhelmina Ziekenhuis Nijmegen Netherlands
3University of Toronto Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinhard Vieth
3University of Toronto Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trygve Holmøy
4Akershus University Hospital and University of Oslo Oslo Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt Marhardt
5Merck GmbH Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myriam Schluep
6Service de Neurologie, Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joep Killestein
7Department of Neurology, VU University Medical Centre Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Barkhof
8Radiology and Nuclear Medicine, VU University Medical Centre Amsterdam Netherlands
9Institutes of Neurology & Healthcare Engineering, University College London Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luigi Maria Grimaldi
10U.O.C. Neurologia and Multiple Sclerosis Center, Fondazione Istituto G. Giglio di Cefalù Cefalù Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manolo Beelke
11Worldwide Clinical Trials GmbH Germering Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a) (S44.005)
Raymond Hupperts, Joost Smolders, Reinhard Vieth, Trygve Holmøy, Kurt Marhardt, Myriam Schluep, Joep Killestein, Frederik Barkhof, Luigi Maria Grimaldi, Manolo Beelke
Neurology Apr 2017, 88 (16 Supplement) S44.005;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: The SOLAR study (NCT01285401) investigated the effects of vitamin D3 (cholecalciferol) as add-on to scIFN β-1a.

Background: The role of vitamin D supplementation in MS disease progression remains uncertain.

Design/Methods: A prospective, randomized, double-blind, multicenter, 48-week study. Patients with RRMS and 25-hydroxyvitamin D serum concentration ≤150 nmol/L were randomized to 44 μg scIFNβ-1a tiw plus either cholecalciferol (14,007 IU [350 μg]) or placebo. Primary endpoint: % subjects disease activity free (DAF) at Week 48, defined as the absence of relapses, EDSS progression or new combined unique active (CUA) lesions. Due to recruitment delays, the original primary endpoint was changed, allowing study duration and sample size to be reduced. Secondary endpoints at Week 48: mean ARR, % subjects free from any EDSS progression and mean number of new CUA lesions/subject/scan.

Results: 229 patients were randomized to cholecalciferol or placebo. The ITT population (81.2%) had a follow-up of 48 weeks. Demographics and disease activity at baseline were similar between groups. At Week 48 there were no significant differences in DAF status between cholecalciferol and placebo (37.2% versus 35.3%; p=0.912). No significant differences between groups were observed for mean ARR (0.28 versus 0.41; p=0.165) or % subjects free from any EDSS progression (71.7% versus 75.0%; p=0.566). At Week 48, cholecalciferol was associated with a 32% reduction in the number of new CUA lesions versus placebo (p=0.005). The % of subjects free from new T1-hypointense lesions was significantly higher with cholecalciferol versus placebo in patients aged 18–30 years (85.7% versus 46.8%; p=0.006), but not in the ITT population.

Conclusions: Although the primary endpoint was not met, SOLAR did show evidence for the effect of vitamin D3 supplementation in patients with RRMS, in terms of fewer new CUA lesions. Cholecalciferol supplementation might be more effective in early stages of disease where intense inflammatory activity is likely.

Disclosure: Dr. Hupperts has received personal compensation for activities with Biogen, Merck Serono, Novartis, Sanofi-Aventis as a speaker. Dr. Hupperts has received research support from Biogen and Merck Serono. Dr. Smolders has nothing to disclose. Dr. Vieth has received personal compensation for activities with the Council for Responsible Nutrition, DiaSorin, Merck, and Novartis, Wyeth, and Yoplait as a speaker. Dr. Vieth has received personal compensation for activities with Cytochroma Inc, D Drops Company, DiaSorin and DSM Nutritionals as a scientific consultant. Dr. Vieth has received royalty payments for an infant vitamin D supplement. Dr. Holmøy has received personal compensation for activities with Merck, Biogen Idec, Sanofi and Novartis as a speaker. Dr. Holmøy has received research support from The Research Council of Norway and The Norwegian South-Eastern Health Authorities. Dr. Marhardt has personal compensation for activities with Merck as an employee. Dr. Schluep has received personal compensation for activities with Biogen, Genzyme, Merck, Novartis, Roche and Sanofi-Aventis as a speaker and consultant. Dr. Schluep has received research support from Merck, Novartis and Biogen. Dr. Killestein has received personal compensation for activities with Merck, Biogen, Teva, Genzyme, Roche and Novartis as a speaker and consultant. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Sanofi Genzyme, Janssen Research, Merck Serono, Novartis, Roche, Synthon BV, and Teva Neuroscience as a consultant or a speaker. Dr. Grimaldi has received personal compensation for activities with Bayer HealthCare, Biogen, Merck Serono, Sanofi-Aventis, and Teva as an advisory board member and a speaker. Dr. Grimaldi has received research support from Biogen and the Serono Foundation. Dr. Beelke has received personal compensation for activities with Merck KgaA as an employee.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise